Skip to main content

Table 3 Comparison of LV remodeling and function between EPO-transduced, non-transduced cell or saline injections by two-dimensional echocardiography, before (baseline), or 5 or 9 weeks after MI

From: Transplantation of genetically engineered cardiac fibroblasts producing recombinant human erythropoietin to repair the infarcted myocardium

  EPO-transduced cells (n = 10) Non-transduced cells (n = 9) Saline (n = 9) p
5-week follow-up     
   Heart rate     0.17
Baseline 308.8 ± 12.6 273.8 ± 11.7 273.0 ± 11.6  
5 weeks 252.7 ± 9.5 252.5 ± 14.0 262.8 ± 13.5  
p* 0.0068 0.32 0.55  
   AW d (cm)     0.07
Baseline 0.13 ± 0.01 0.17 ± 0.007 0.13 ± 0.01  
5 weeks 0.09 ± 0.006 0.10 ± 0.01 0.10 ± 0.01  
p* 0.006 0.0002 0.04  
   LVEDD     0.08
Baseline 0.76 ± 0.02 0.72 ± 0.02 0.82 ± 0.02  
5 weeks 1.06 ± 0.02 0.98 ± 0.03 1.00 ± 0.03  
p* <0.0001 <0.0001 0.0009  
   LVESD     0.22
Baseline 0.60 ± 0.03 0.56 ± 0.02 0.64 ± 0.03  
5 weeks 0.88 ± 0.03 0.81 ± 0.04 0.80 ± 0.04  
p* <0.0001 <0.0001 <0.0001  
   LVEDA     0.34
Baseline 0.39 ± 0.03 0.35 ± 0.01 0.43 ± 0.02  
5 weeks 0.73 ± 0.04 0.65 ± 0.04 0.67 ± 0.05  
p* <0.0001 <0.0001 0.0011  
   LVESA     0.36
Baseline 0.24 ± 0.02 0.21 ± 0.01 0.26 ± 0.02  
5 weeks 0.52 ± 0.04 0.42 ± 0.04 0.44 ± 0.05  
p* <0.0001 <0.0001 0.0004  
   FS (%)     0.99
Baseline 20.6 ± 2.9 22.3 ± 1.7 25.07 ± 2.2  
5 weeks 16.2 ± 1.4 17.8 ± 1.6 20.96 ± 2.0  
p* 0.14 0.008 0.002  
9-week follow-up     
   Heart rate     0.28
Baseline 303.2 ± 12.7 274.4 ± 13.3 273.0 ± 11.6  
9 weeks 242.0 ± 6.3 235.5 ± 12.2 246.2 ± 7.7  
p* 0.04 0.12 0.0014  
   AW d (cm)     0.19
Baseline 0.13 ± 0.01 0.17 ± 0.007 0.13 ± 0.01  
9 weeks 0.09 ± 0.01 0.12 ± 0.01 0.11 ± 0.01  
p* 0.03 0.0002 0.3  
   LVEDD     0.22
Baseline 0.76 ± 0.02 0.72 ± 0.02 0.82 ± 0.02  
9 weeks 1.11 ± 0.04 1.03 ± 0.03 1.05 ± 0.03  
p* <0.0001 <0.0001 0.0003  
   LVESD     0.3
Baseline 0.60 ± 0.03 0.56 ± 0.02 0.64 ± 0.03  
9 weeks 0.95 ± 0.05 0.84 ± 0.04 0.86 ± 0.05  
p* <0.0001 <0.0001 <0.0001  
   LVEDA     0.42
Baseline 0.39 ± 0.03 0.35 ± 0.01 0.43 ± 0.02  
9 weeks 0.83 ± 0.06 0.71 ± 0.05 0.74 ± 0.06  
p* <0.0001 <0.0001 0.0006  
   LVESA     0.37
Baseline 0.24 ± 0.02 0.21 ± 0.01 0.26 ± 0.02  
9 weeks 0.61 ± 0.06 0.48 ± 0.05 0.51 ± 0.06  
p* 0.0001 0.0001 0.0003  
   FS (%)     0.09
Baseline 20.6 ± 2.9 22.3 ± 1.72 25.1 ± 2.2  
9 weeks 14.3 ± 1.8 18.7 ± 1.73 19.8 ± 2.4  
p* 0.05 0.02 0.0008  
  1. AW d, anterior wall diastolic thickness; LVEDD, LV end diastolic dimension; LVESD, LV end systolic dimension; LVEDA, LV end diastolic area; LVESA, LV end systolic area; FS, LV fractional shortening [(LVIDd – LVIDs)/LVIDd] × 100. Values are mean ± SEM; p*, p-values derived from paired comparisons between baseline and 5/9 week measurements; p, p-values for the differences between groups over time (two-way repeated-measures ANOVA, p-value for interaction).